The effects of mutant Ras proteins on the cell signalome
-
Published:2020-07-09
Issue:4
Volume:39
Page:1051-1065
-
ISSN:0167-7659
-
Container-title:Cancer and Metastasis Reviews
-
language:en
-
Short-container-title:Cancer Metastasis Rev
Author:
Takács Tamás,Kudlik Gyöngyi,Kurilla Anita,Szeder Bálint,Buday László,Vas Virag
Abstract
AbstractThe genetic alterations in cancer cells are tightly linked to signaling pathway dysregulation. Ras is a key molecule that controls several tumorigenesis-related processes, and mutations in RAS genes often lead to unbiased intensification of signaling networks that fuel cancer progression. In this article, we review recent studies that describe mutant Ras-regulated signaling routes and their cross-talk. In addition to the two main Ras-driven signaling pathways, i.e., the RAF/MEK/ERK and PI3K/AKT/mTOR pathways, we have also collected emerging data showing the importance of Ras in other signaling pathways, including the RAC/PAK, RalGDS/Ral, and PKC/PLC signaling pathways. Moreover, microRNA-regulated Ras-associated signaling pathways are also discussed to highlight the importance of Ras regulation in cancer. Finally, emerging data show that the signal alterations in specific cell types, such as cancer stem cells, could promote cancer development. Therefore, we also cover the up-to-date findings related to Ras-regulated signal transduction in cancer stem cells.
Funder
ELKH Research Centre for Natural Sciences
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference127 articles.
1. Buday, L., & Downward, J. (2008). Many faces of Ras activation. Biochimica et Biophysica Acta, 1786(2), 178–187. https://doi.org/10.1016/j.bbcan.2008.05.001. 2. Xu, J., Pfarr, N., Endris, V., Mai, E. K., Md Hanafiah, N. H., Lehners, N., Penzel, R., Weichert, W., Ho, A. D., Schirmacher, P., Goldschmidt, H., Andrulis, M., & Raab, M. S. (2017). Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation. Oncogenesis, 6(5), e337–e337. https://doi.org/10.1038/oncsis.2017.36. 3. Riquelme, E., Behrens, C., Lin, H. Y., Simon, G., Papadimitrakopoulou, V., Izzo, J., et al. (2016). Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations. Cancer Research, 76(3), 675–685. https://doi.org/10.1158/0008-5472.CAN-15-1141. 4. Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., Persaud, Y., Levine, D. A., Fagin, J. A., Jhanwar, S. C., Mariadason, J. M., Lash, A., Ladanyi, M., Saltz, L. B., Heguy, A., Paty, P. B., & Solit, D. B. (2010). Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Research, 70(14), 5901–5911. https://doi.org/10.1158/0008-5472.CAN-10-0192. 5. Leiser, D., Medová, M., Mikami, K., Nisa, L., Stroka, D., Blaukat, A., Bladt, F., Aebersold, D. M., & Zimmer, Y. (2015). KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. Molecular Oncology, 9(7), 1434–1446. https://doi.org/10.1016/j.molonc.2015.04.001.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|